On May 7, 2018 National Cancer Center (Tokyo Japan, President: Hitoshi Nakagama) and Carna Biosciences, Inc (Kobe Japan, President and CEO: Kohichiro Yoshino) reported that they have entered into a research
collaboration agreement to discover novel therapeutic interventions in cancers (Press release, Carna Biosciences, MAY 7, 2018, View Source [SID1234526520]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, National Cancer Center and Carna Biosciences will collaborate on drug discovery research to develop a novel anticancer drug with new mechanisms of action that have been discovered by Dr. Kenkichi Masutomi, Chief, Division of Cancer Stem Cell at National Cancer Center Research Institute.

During the research term, both parties will leverage their respective expertise, including Carna’s extensive expertise in small molecule drug discovery with its powerful drug discovery engine and National Cancer Center’s profound knowledge of cancer research.

National Cancer Center and Carna Biosciences have been working together successfully under a research collaboration since 2008 to research and develop new drugs targeting WNT signal. This new collaboration agreement will further strengthen the relationship between both parties, which enables to accelerate the development of novel anti-cancer drugs to bring innovative treatment to cancer patients.